Regulatory News
Friday, June 17, 2016
BRIEF-FDA Accepts Emergent BioSolutions' supplemental biologics license application for large-scale manufacturing of BioThrax in Building 55
* FDA has set a prescription drug user fee act (PDUFA)
target action date of august 15, 2016
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment